Obesity is imposing a substantial economic burden on the United Kingdom, with recent research estimating a cost of nearly £20 billion due to weight-related illness leading to reduced workforce participation and productivity losses. The findings suggest that Britain faces greater productivity setbacks associated with excess body fat than other major European nations, including Germany, France, Italy, and Spain.
A report by the Office for Health Economics, an independent research organization, highlights that the UK’s economic losses attributable to obesity-related factors exceed those of eight compared European countries combined. The analysis estimates the total annual cost of excess weight in the UK at approximately £33.8 billion, which includes £19.6 billion in productivity losses and £14.2 billion in healthcare expenses. This sums to about £488 per person and corresponds to roughly 1.4 percent of the country's gross domestic product (GDP).
Breaking down the productivity losses, the study attributes nearly £8 billion to workforce departures caused by ill health. Reduced productivity among employees working while unwell accounts for £5.4 billion, and sick leave contributes a further £2.4 billion in economic costs. Additionally, unpaid care provided by family members and friends represents an estimated £2.6 billion in lost value, while premature deaths result in indirect losses of £1.4 billion.
The report also reveals that Britain carries the highest per capita economic cost of obesity among the countries studied—£311 per person—compared with £268 in Ireland and £256 in Germany. Notably, Britain’s £19.6 billion productivity loss approximates that of Germany, despite Germany’s larger population.
Researchers attribute Britain’s particularly high economic burden in part to a rise in long-term sickness and economic inactivity connected to obesity, trends that differ from other European countries where such inactivity has been declining since the COVID-19 pandemic. The findings underscore the need for more robust public health interventions and policies targeting obesity.
The study calls attention to limited access to new weight-loss medications through the National Health Service (NHS), characterizing availability as “severely restricted.” It emphasizes that potential benefits of pharmacological obesity treatments on employment and productivity should be factored into policy and funding decisions. Previous research cited indicates that obese employees are twice as likely to take sick leave compared to non-obese colleagues, while those receiving weight-loss drugs have experienced halving of sick days.
Wes Streeting, the Health Secretary, has initiated pilot projects to examine the effects of weight-loss medication on reducing worklessness, reflecting growing official interest in the issue. The research was commissioned and funded by the European Federation of Pharmaceutical Industries and Associations (EFPIA).